Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases
03. September 2014 05:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead
first-in-class inflammation/auto-immune assets, RP6503 and RP3128
in...